Biogen
Innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases.
Launch date
Employees
Market cap
€26.2b
Enterprise valuation
€30.5b (Public information from Sep 2024)
Share price
$201.44 BIIB
Cambridge Massachusetts (HQ)
Corporate Venture Fund: Biogen Idec New Ventures
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 13.4b | 11.0b | 10.2b | 9.8b | 9.6b | 9.6b | 9.8b |
% growth | (6 %) | (18 %) | (7 %) | (3 %) | (2 %) | - | 2 % |
EBITDA | 4.8b | 3.7b | 2.7b | 2.6b | 3.3b | 3.5b | 3.7b |
% EBITDA margin | 36 % | 33 % | 26 % | 26 % | 35 % | 36 % | 38 % |
Profit | 4.0b | 1.6b | 3.0b | 1.2b | 1.9b | 2.2b | 2.5b |
% profit margin | 30 % | 14 % | 30 % | 12 % | 20 % | 23 % | 25 % |
EV / revenue | 3.1x | 3.4x | 4.0x | 4.4x | 3.4x | 3.2x | 2.8x |
EV / EBITDA | 8.7x | 10.3x | 15.1x | 16.7x | 9.9x | 8.8x | 7.3x |
R&D budget | 4.0b | 2.5b | 2.2b | 2.5b | - | - | - |
R&D % of revenue | 30 % | 23 % | 22 % | 25 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
N/A | $2.1m | Grant | |
Total Funding | €1.9m |
Recent News about Biogen
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
ACQUISITION by Alkermes Nov 2019
ACQUISITION by Bioverativ May 2017
ACQUISITION by Biogen Feb 2014
ACQUISITION by LG Chem Oct 2022
ACQUISITION Dec 2011
ACQUISITION by Momenta Pharmaceuticals Dec 2011